News

Forge Therapeutics, Inc. (Forge) and Basilea Pharmaceutica International Ltd. (Basilea), a wholly-owned subsidiary of Basilea Pharmaceutica Ltd., announced that they have entered into a…
Read More...

La Jolla Pharmaceutical Company announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for the New Investigational Drug Product,…
Read More...

Forbius, a clinical-stage company that develops novel biologics for the treatment of fibrosis and cancer, announced that the first patient has been dosed in a Phase 1b trial assessing…
Read More...

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases with high unmet…
Read More...

ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), and Adagene Inc., an antibody…
Read More...

Velabs Therapeutics announced that it has entered into an agreement with Chiome Bioscience, Inc., Tokyo, to jointly discover modulatory and functional antibodies for one of Chiome’s…
Read More...

Fulcrum Therapeutics announced an exclusive worldwide license agreement with GlaxoSmithKline (GSK) for development and commercialization of the investigational drug losmapimod. Fulcrum…
Read More...

AbbVie announced that the U.S. Food and Drug Administration (FDA) approved SKYRIZI (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor, for the treatment of moderate to severe…
Read More...

Teva Pharmaceutical Industries Ltd. provided an update that the Company is discontinuing the clinical development program for use of fremanezumab in cluster headaches. A pre-specified…
Read More...

FSD Pharma Inc. and Prismic Pharmaceuticals Inc. announced that they have entered into a securities exchange agreement dated April 22, 2019 (the “Agreement”) pursuant to which FSD…
Read More...

UroGen Pharma Ltd. announced that it has entered into an agreement with Janssen Research & Development, LLC (Janssen) to conduct an early-stage feasibility evaluation in a…
Read More...

On April 19, 2019, the Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck & Co. Inc.) plus axitinib for the first-line treatment of patients with advanced renal…
Read More...

Oakrum Pharma, LLC (Oakrum) announced that it has entered into an agreement with Biophore India Pharmaceuticals Pvt. Ltd. (Biophore) to develop and manufacture two prescription generic…
Read More...

Elpiscience BioPharma and Bio-Techne Corporation announced that the companies have entered into a strategic collaboration for the development of anti-cancer therapeutics. Under the…
Read More...

Eli Lilly and Company and Avidity Biosciences, Inc. announced a global licensing and research collaboration focused on the discovery, development and commercialization of potential new…
Read More...

Teva Pharmaceutical Industries Ltd. announced the launch of a generic version of VESIcare ®1 (solifenacin succinate) Tablets, 5 mg and 10 mg, in the U.S. Solifenacin Succinate…
Read More...

Pfizer Inc. and Eli Lilly and Company announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg. The objective of the study was to compare the long-term joint…
Read More...

Non-profit drug developer, TB Alliance, and pharmaceutical company, Mylan N.V. announced a global collaboration to make the experimental drug pretomanid accessible for use in two…
Read More...

Ipsen and Clementia Pharmaceuticals announced the closing of Ipsen’s acquisition of Clementia following approval of the arrangement by Clementia shareholders and the Quebec Superior…
Read More...

SK Biopharmaceuticals, a pharmaceutical company focused on disorders of central nervous system and cancer, and twoXAR, Inc., an artificial intelligence (AI)-driven biopharmaceutical…
Read More...